BioTelemetry Inc. (NASDAQ:BEAT) General Counsel Peter Ferola sold 4,352 shares of the company’s stock in a transaction that occurred on Tuesday, September 13th. The shares were sold at an average price of $18.23, for a total value of $79,336.96. Following the completion of the transaction, the general counsel now directly owns 30,989 shares of the company’s stock, valued at approximately $564,929.47. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Peter Ferola also recently made the following trade(s):

  • On Thursday, September 8th, Peter Ferola sold 2,210 shares of BioTelemetry stock. The shares were sold at an average price of $18.10, for a total value of $40,001.00.
  • On Friday, September 2nd, Peter Ferola sold 4,856 shares of BioTelemetry stock. The shares were sold at an average price of $18.75, for a total value of $91,050.00.
  • On Tuesday, September 6th, Peter Ferola sold 4,960 shares of BioTelemetry stock. The shares were sold at an average price of $18.29, for a total value of $90,718.40.
  • On Wednesday, September 7th, Peter Ferola sold 14,053 shares of BioTelemetry stock. The shares were sold at an average price of $18.52, for a total value of $260,261.56.
  • On Thursday, September 1st, Peter Ferola sold 7,722 shares of BioTelemetry stock. The shares were sold at an average price of $18.59, for a total transaction of $143,551.98.
  • On Tuesday, August 30th, Peter Ferola sold 12,970 shares of BioTelemetry stock. The shares were sold at an average price of $19.07, for a total transaction of $247,337.90.
  • On Thursday, August 25th, Peter Ferola sold 6,289 shares of BioTelemetry stock. The shares were sold at an average price of $19.16, for a total transaction of $120,497.24.
  • On Wednesday, August 24th, Peter Ferola sold 6,512 shares of BioTelemetry stock. The shares were sold at an average price of $20.11, for a total transaction of $130,956.32.
  • On Tuesday, August 23rd, Peter Ferola sold 2,758 shares of BioTelemetry stock. The shares were sold at an average price of $20.67, for a total transaction of $57,007.86.
  • On Monday, August 22nd, Peter Ferola sold 3,616 shares of BioTelemetry stock. The shares were sold at an average price of $20.85, for a total transaction of $75,393.60.

Shares of BioTelemetry Inc. (NASDAQ:BEAT) opened at 18.44 on Monday. The stock’s 50 day moving average is $19.71 and its 200 day moving average is $15.86. The firm has a market cap of $516.78 million, a P/E ratio of 39.23 and a beta of 0.81. BioTelemetry Inc. has a 12 month low of $8.74 and a 12 month high of $21.42.

BioTelemetry (NASDAQ:BEAT) last issued its quarterly earnings results on Tuesday, August 2nd. The company reported $0.20 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.17 by $0.03. The firm earned $52.68 million during the quarter, compared to the consensus estimate of $50.27 million. BioTelemetry had a return on equity of 25.36% and a net margin of 7.11%. The company’s revenue for the quarter was up 17.6% on a year-over-year basis. During the same quarter last year, the company posted $0.12 EPS. Equities research analysts expect that BioTelemetry Inc. will post $0.76 EPS for the current year.

A number of analysts have weighed in on BEAT shares. Zacks Investment Research raised shares of BioTelemetry from a “hold” rating to a “buy” rating and set a $23.00 target price for the company in a research report on Thursday, August 4th. Sidoti started coverage on shares of BioTelemetry in a research report on Tuesday, September 13th. They set a “buy” rating and a $27.00 target price for the company. Finally, Benchmark Co. increased their target price on shares of BioTelemetry from $20.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, August 3rd.

Several hedge funds have recently modified their holdings of the stock. State Street Corp increased its stake in shares of BioTelemetry by 11.8% in the first quarter. State Street Corp now owns 466,925 shares of the company’s stock worth $5,452,000 after buying an additional 49,274 shares during the period. Springbok Capital Management LLC acquired a new stake in shares of BioTelemetry during the first quarter worth about $146,000. Mckinley Capital Management LLC Delaware acquired a new stake in shares of BioTelemetry during the second quarter worth about $7,636,000. SECOR Capital Advisors LP acquired a new stake in shares of BioTelemetry during the second quarter worth about $1,371,000. Finally, Panagora Asset Management Inc. increased its stake in shares of BioTelemetry by 27.2% in the first quarter. Panagora Asset Management Inc. now owns 235,826 shares of the company’s stock worth $2,754,000 after buying an additional 50,460 shares during the period. Hedge funds and other institutional investors own 78.28% of the company’s stock.

About BioTelemetry

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

5 Day Chart for NASDAQ:BEAT

Receive News & Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.